ATARA Biotherapeutics (ATRA) Misses Q1 EPS by 35c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q1 EPS of ($0.72), $0.35 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $1.23 million versus the consensus estimate of $32.01 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• General Mills beats estimates as cost savings offset volumes
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance